Adagene Inc.ADAG
Oncology23 cited findings · profile updated 2026-08-20
4.12 USDnot live — refreshed daily
About Adagene Inc.
Adagene Inc. is an oncology research site with a focus on muzastotug. In studies involving muzastotug + atezolizumab + bevacizumab, an overall response rate (ORR) of 66.7% was observed using HCC-specified modified RECIST v1.1, compared to 32.5% for the active control arm of atezolizumab + bevacizumab. The median progression-free survival (PFS) for muzastotug + atezolizumab + bevacizumab was 8.2 months, while the active control arm showed 5.5 months. Median overall survival (OS) for muzastotug + atezolizumab + bevacizumab was >22 months, compared to 17.5 months for the active control arm.
Muzastotug has also been studied in combination with pembrolizumab. Muzastotug (20 mg/kg loading dose) + pembrolizumab demonstrated an overall response rate (ORR) of 36% and a median progression-free survival (PFS) of 15.4 months. For muzastotug (20 mg/kg) + pembrolizumab, the confirmed overall response rate (ORR) was 31% and the median progression-free survival (PFS) was 6.7 months. The primary endpoint for muzastotug in neoadjuvant MSS CRC is the rate of Major Pathologic Response (MPR).
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Overall Response Rate (ORR) using HCC-specified modified RECIST v1.1 | 66.7% for muzastotug + atezolizumab + bevacizumab vs 32.5% for atezolizumab + bevacizumab (active control arm) | Adagene Inc. — SEC 6-K (2026-08-12), p.p.3 |
| Median Progression-Free Survival (PFS) | 8.2 months for muzastotug + atezolizumab + bevacizumab vs 5.5 months for atezolizumab + bevacizumab (active control arm) | Adagene Inc. — SEC 6-K (2026-08-12), p.p.3 |
| Median Overall Survival (OS) | >22 months for muzastotug + atezolizumab + bevacizumab vs 17.5 months for atezolizumab + bevacizumab (active control arm) | Adagene Inc. — SEC 6-K (2026-08-12), p.p.3 |
| Overall Response Rate (ORR) | 36% for muzastotug (20 mg/kg loading dose) + pembrolizumab | Adagene Inc. — SEC 6-K (2026-08-12), p.p.2 |
| Median Progression-Free Survival (PFS) | 15.4 months for muzastotug (20 mg/kg loading dose) + pembrolizumab | Adagene Inc. — SEC 6-K (2026-08-12), p.p.2 |
| Confirmed Overall Response Rate (ORR) | 31% for muzastotug (20 mg/kg) + pembrolizumab | Adagene Inc. — SEC 6-K (2026-08-12), p.p.2 |
Key projects
- muzastotug + atezolizumab + bevacizumab
An overall response rate (ORR) of 66.7% using HCC-specified modified RECIST v1.1 was observed, compared to 32.5% for atezolizumab + bevacizumab (active control arm).
- muzastotug (20 mg/kg loading dose) + pembrolizumab
This combination showed an overall response rate (ORR) of 36%.
- muzastotug (20 mg/kg) + pembrolizumab
This combination demonstrated a confirmed overall response rate (ORR) of 31%.
- muzastotug in neoadjuvant MSS CRC
The primary endpoint is the rate of Major Pathologic Response (MPR).
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →